ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

VIRI Virios Therapeutics Inc

0.41
-0.0015 (-0.36%)
Fuera de horario
Última actualización: 15:30:00
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Virios Therapeutics Inc VIRI NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.0015 -0.36% 0.41 15:30:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.428 0.402 0.4288 0.41 0.4115
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
02/5/202408:15GLOBEVirios Therapeutics to Report First Quarter 2024 Financial..
26/3/202408:15GLOBEVirios Therapeutics Announces Publication of International..
08/3/202416:00EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
06/3/202415:30EDGAR2Form 8-K - Current report
01/3/202408:10EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202408:25EDGAR2Form 8-K - Current report
29/2/202408:15GLOBEVirios Therapeutics Announces Fourth Quarter and Full Year..
28/2/202412:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202412:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202411:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202411:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202411:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202411:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202411:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202411:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202408:15GLOBEVirios Therapeutics Issues Shareholder Letter..
27/2/202415:15EDGAR2Form 8-K - Current report
02/2/202415:31EDGAR2Form DEF 14A - Other definitive proxy statements
22/1/202408:33EDGAR2Form PRE 14A - Other preliminary proxy statements
22/1/202408:00GLOBEVirios Therapeutics Announces Plans to Advance..
03/1/202406:05EDGAR2Form 8-K - Current report
02/1/202406:05GLOBEVirios Therapeutics, Inc. Reaches Alignment with FDA on..
13/11/202308:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202306:20EDGAR2Form 8-K - Current report
13/11/202306:05GLOBEVirios Therapeutics Announces Third Quarter 2023 Financial..
07/11/202306:29EDGAR2Form 8-K - Current report
06/11/202306:05GLOBEVirios Therapeutics to Report Third Quarter 2023 Financial..
02/11/202306:05EDGAR2Form 8-K - Current report
12/10/202306:05GLOBEVirios Therapeutics to Present at the ThinkEquity Conference..
18/9/202306:16EDGAR2Form 8-K - Current report
18/9/202306:05GLOBEVirios Therapeutics Announces Termination of At-The-Market..
12/9/202306:05GLOBEVirios Therapeutics CEO Greg Duncan to Present at the..
22/8/202314:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/8/202306:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202306:05GLOBEVirios Therapeutics Announces Halt to At-The-Market Offering..
11/8/202307:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202306:15EDGAR2Form 8-K - Current report
10/8/202306:05GLOBEVirios Therapeutics Announces Second Quarter 2023 Financial..
09/8/202306:15EDGAR2Form 8-K - Current report
09/8/202306:05GLOBEVirios Therapeutics Announces Plans to Advance Lead..
03/8/202315:05GLOBEVirios Therapeutics to Report Second Quarter 2023 Financial..
17/7/202306:15EDGAR2Form 8-K - Current report
17/7/202306:05GLOBEVirios Therapeutics Announces Positive Data Demonstrating..
14/7/202315:25EDGAR2Form 8-K - Current report
14/7/202315:12EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
25/5/202315:05GLOBEVirios Therapeutics Regains Compliance with Nasdaq Minimum..
15/5/202306:05GLOBEVirios Therapeutics Announces Submission of Final Toxicology..
11/5/202306:05GLOBEVirios Therapeutics Announces First Quarter 2023 Financial..

Su Consulta Reciente

Delayed Upgrade Clock